Search company, investor...

Valderm Aps

valderm.dk

Stage

Other Investors | Alive

About Valderm Aps

Valderm ApS is focused on the development of the second generation anthracycline valrubicin for once daily topical treatment of hyperproliferative skin diseases e.g. psoriasis.

Headquarters Location

Kongevejen 75A

2800,

Denmark

Missing: Valderm Aps's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Valderm Aps's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Valderm Aps Patents

Valderm Aps has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/28/2008

9/11/2012

Anthracyclines, Monoclonal antibodies, Immunosuppressants, Phenols, Selective estrogen receptor modulators

Grant

Application Date

1/28/2008

Grant Date

9/11/2012

Title

Related Topics

Anthracyclines, Monoclonal antibodies, Immunosuppressants, Phenols, Selective estrogen receptor modulators

Status

Grant

Valderm Aps Frequently Asked Questions (FAQ)

  • What is Valderm Aps's latest funding round?

    Valderm Aps's latest funding round is Other Investors.

  • Who are the investors of Valderm Aps?

    Investors of Valderm Aps include SEED Capital.

  • Who are Valderm Aps's competitors?

    Competitors of Valderm Aps include Tobira Therapeutics, Anacor Pharmaceuticals, Tioga Pharmaceuticals, Lux Biosciences, Peptimmune and 9 more.

Compare Valderm Aps to Competitors

Topica Logo
Topica

Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.

M
MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada.

I
Inagen Aps

Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.

K
Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

L
Lytix Biopharma

Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology

P
Photopharmica

Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.